TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A consortium co-led by the Buck Institute and Georgetown University has received an ARPA-H award of up to $51.7 million for a four-year project on proteins that can shift into disease-associated states. The team plans to combine computational modeling and experiments, initially studying proteins relevant to Alzheimer’s disease and Ewing sarcoma. The award funds research; it does not establish that new diagnostic tests or treatments will result.
A consortium co-led by the Buck Institute for Research on Aging and Georgetown University has received an award of up to $51.7 million from the Advanced Research Projects Agency for Health to study how disease-linked proteins change shape before they cause lasting cellular damage. The four-year project will initially focus on Alzheimer’s disease and Ewing sarcoma, aiming to build predictive tools that could inform future diagnostics and treatments.
The consortium, called SEEDS — Sequence-to-disease: Environment-aware Ensembles of Disordered proteins at Scale — will study intrinsically disordered proteins, or IDPs. Unlike proteins that settle into a relatively stable three-dimensional structure, IDPs can take many forms. Their behavior may depend on conditions inside cells, including acidity, molecular crowding, metals, metabolites and chemical modifications.
Researchers will combine physics-guided artificial intelligence and computational modeling with laboratory measurements. The experiments are intended to test and refine model predictions under different conditions, rather than relying on computer forecasts alone. The consortium includes researchers from nine academic institutions and seven industry partners, and brings together expertise in protein science, cancer, neuroscience and computation.
The project’s goal is to learn how protein sequence and cellular surroundings relate to changes in protein behavior, then investigate whether harmful shifts can be detected or redirected. The source report describes this as a research aim, not an established capability. It does not specify particular diagnostic products, treatments, clinical trials or a timeline for patient use.
Why Early Protein Changes Matter
Protein misfolding and aggregation are associated with Alzheimer’s disease, amyotrophic lateral sclerosis and some cancers, among other chronic and degenerative conditions. Studying changes that happen before proteins clump could help researchers investigate processes that are difficult to observe after damage has accumulated. That makes the project’s focus on early behavior scientifically relevant, even though the award itself does not show that the team can predict disease onset in people.
Some disease-associated proteins are considered difficult to target with conventional medicines because they lack stable structures and binding pockets that many drug designs rely on. If SEEDS produces reliable ways to describe how these flexible proteins behave in different cellular environments, that information could support future research into detection or intervention. Any such clinical benefit remains uncertain and would require further validation.
As an affiliate, we earn on qualifying purchases.
The Challenge of Disordered Proteins
Many protein research tools work by studying stable structures. The source report says researchers can capture snapshots of intrinsically disordered proteins, sometimes after they have already aggregated, but cannot yet reliably predict how those proteins will behave as conditions inside cells change or when a shift becomes harmful.
Artificial-intelligence systems such as AlphaFold have advanced protein science by learning from large bodies of structural data. Buck Institute co-lead Chuankai (Kai) Zhou said there is less comparable structural information for IDPs, making their behavior harder to model. SEEDS is part of ARPA-H’s BIOmolecular Grammar for protein Aggregation Modulation and Intervention program, which focuses on early stages of protein dysfunction.
The consortium draws together Georgetown’s INTREPID and the Buck Institute’s SHIFT teams. The program uses “molecular grammar” as a way to describe the rules linking protein sequence and surroundings to behavior; the researchers aim to investigate those rules through large-scale study and focused experiments.
“We aim to uncover the principles that determine when these proteins remain in healthy functional ensembles and when they begin to shift toward disease-associated states.”
— Chuankai (Kai) Zhou, assistant professor at the Buck Institute
As an affiliate, we earn on qualifying purchases.
What the Award Cannot Yet Show
The announcement does not report that SEEDS has already developed a predictive model, identified a clinical marker or produced a treatment. It also does not give a detailed breakdown of how the award will be distributed, specify which individual proteins will be studied, or describe measurable milestones for the four-year effort.
It remains unknown whether models trained on the selected proteins and experimental conditions will predict behavior reliably in living cells or people. The proposed work may generate insights that support future diagnostics or treatments, but the timing, feasibility and clinical value of those applications have not been established.
AI-based protein analysis software
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Research Plans Over Four Years
Over the four-year award period, the consortium plans to generate data on how selected disordered proteins behave under varying conditions, develop predictive approaches and compare model outputs with experimental measurements. The initial research focus is Alzheimer’s disease and Ewing sarcoma.
The next meaningful updates would include details on the proteins and experiments selected, evidence showing how well the models predict measured behavior, and whether the findings point to testable diagnostic or treatment strategies. The source report does not provide dates for those milestones or say when results will be published.
laboratory protein measurement equipment
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Who is leading the SEEDS effort?
The consortium is co-led by Priyanka Joshi of Georgetown University and Chuankai (Kai) Zhou of the Buck Institute, with researchers from nine academic institutions and seven industry partners.
How much funding did the project receive?
ARPA-H awarded the effort up to $51.7 million. The source report describes the project as a four-year effort but does not give a funding disbursement schedule.
What proteins will researchers study?
The team will study intrinsically disordered proteins, which can take multiple forms and may behave differently as conditions inside cells change. The initial disease focus is Alzheimer’s disease and Ewing sarcoma; the report does not name specific proteins.
Does the award mean new tests or treatments are ready?
No. The award supports research intended to improve understanding and prediction of protein behavior. The announcement reports goals, not completed diagnostics or treatments, and gives no timeline for clinical use.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
